Publication | Open Access

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

MedicineMelanomaPathologyImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyMolecular Oncology